Literature DB >> 26131051

Prognostic and clinicopathological significance of MACC1 expression in hepatocellular carcinoma patients: a meta-analysis.

Da-Wei Sun1, Ying-Yi Zhang2, Yue Qi3, Gui-Qi Liu1, Yu-Guo Chen1, Jian Ma1, Guo-Yue Lv1.   

Abstract

OBJECTIVE: Metastasis-associated in colon cancer-1 (MACC1) has been reported to be overexpressed in diverse human malignancies. However, the prognostic and clinicopathological value of MACC1 in hepatocellular carcinoma (HCC) remains inconclusive. Therefore, we conducted this meta-analysis to investigate the association between MACC1 expression and the outcomes of HCC.
METHODS: Relevant articles were searched in PubMed, Embase, Sciencedirect, CNKI, and Wanfang databases updated to October 2014. The pooled hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were assessed using STATA 10.0, and then the correlations of MACC1 expression with overall survival (OS), disease-free survival (DFS), and clinicopathological features were analyzed.
RESULTS: 9 studies with a total of 1293 HCC patients were included in this meta-analysis. Our results showed that MACC1 over-expression was significantly associated with poor OS (HR = 2.30, 95% CI 1.47-3.59, univariate analysis; HR = 2.39, 95% CI 1.49-3.82, multivariate analysis), poor DFS (HR = 1.73, 95% CI 1.40-2.13, univariate analysis). Moreover, MACC1 over-expression was significantly associated with AFP level (OR = 1.31, 95% CI 1.03-1.68), tumor number (OR = 1.37, 95% CI 1.07-1.75), differentiation (OR = 2.37, 95% CI 1.46-3.83), TNM stage (OR = 2.89, 95% CI 2.18-3.82), vascular invasion (OR = 1.89, 95% CI 1.43-2.50), capsule invasion (OR = 2.89, 95% CI 1.40-5.94), and metastasis (OR = 2.66, 95% CI 1.16-6.10).
CONCLUSION: MACC1 over-expression indicated poor survival rate, high recurrence rate, and aggressive biological behaviors. MACC1 can serve as an indicator of prognosis and a potential novel target for treatment in HCC patients.

Entities:  

Keywords:  HCC; MACC1; meta-analysis; prognosis

Year:  2015        PMID: 26131051      PMCID: PMC4483922     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 3.  Current management of hepatocellular carcinoma.

Authors:  Parissa Tabrizian; Sasan Roayaie; Myron E Schwartz
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 4.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

5.  MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.

Authors:  Ulrike Stein; Wolfgang Walther; Franziska Arlt; Holger Schwabe; Janice Smith; Iduna Fichtner; Walter Birchmeier; Peter M Schlag
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

6.  Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors.

Authors:  Jessica A Davila; Jennifer R Kramer; Zhigang Duan; Peter A Richardson; Gia L Tyson; Yvonne H Sada; Fasiha Kanwal; Hashem B El-Serag
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

7.  Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma.

Authors:  Jiliang Qiu; Pinzhu Huang; Qian Liu; Jian Hong; Binkui Li; Canliang Lu; Li Wang; Jianping Wang; Yunfei Yuan
Journal:  J Transl Med       Date:  2011-09-29       Impact factor: 5.531

8.  MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/β-catenin signaling pathway.

Authors:  Fengjiao Meng; Hui Li; Huijuan Shi; Qingxu Yang; Fenfen Zhang; Yang Yang; Lili Kang; Tiantian Zhen; Sujuan Dai; Yu Dong; Anjia Han
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

9.  Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation.

Authors:  Sheng Gao; Bing-Yi Lin; Zhe Yang; Zhi-Yun Zheng; Zhi-Kun Liu; Li-Ming Wu; Hai-Yang Xie; Lin Zhou; Shu-Sen Zheng
Journal:  Int J Med Sci       Date:  2014-01-21       Impact factor: 3.738

10.  MACC1 promotes carcinogenesis of colorectal cancer via β-catenin signaling pathway.

Authors:  Tiantian Zhen; Sujuan Dai; Hui Li; Yang Yang; Lili Kang; Huijuan Shi; Fenfen Zhang; Dongjie Yang; Shirong Cai; Yulong He; Yingjie Liang; Anjia Han
Journal:  Oncotarget       Date:  2014-06-15
View more
  18 in total

1.  miR-944 inhibits cell migration and invasion by targeting MACC1 in nasopharyngeal carcinoma.

Authors:  Juanjuan Ji; Yi Peng; Tao Niu; Yunhong Lin; Yan Lin; Xudong Li; Xiaoguang Wu; Zhiyong Huang; Ling Zhong; Shinan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

2.  MicroRNA-877 is downregulated in cervical cancer and directly targets MACC1 to inhibit cell proliferation and invasion.

Authors:  Fanxu Meng; Jian Ou; Jinyu Liu; Xindi Li; Yanli Meng; Ling Yan; Ping Deng; Baosheng Sun
Journal:  Exp Ther Med       Date:  2019-09-09       Impact factor: 2.447

3.  The essential role of MTDH in the progression of HCC: a study with immunohistochemistry, TCGA, meta-analysis and in vitro investigation.

Authors:  Rongquan He; Li Gao; Jie Ma; Zhigang Peng; Shengsheng Zhou; Lihua Yang; Zhenbo Feng; Yiwu Dang; Gang Chen
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  MACC1-Induced Collective Migration Is Promoted by Proliferation Rather Than Single Cell Biomechanics.

Authors:  Tim Hohmann; Urszula Hohmann; Mathias Dahlmann; Dennis Kobelt; Ulrike Stein; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

5.  MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1.

Authors:  Dengkun Lv; Zhen Zhen; Defa Huang
Journal:  Exp Ther Med       Date:  2018-11-29       Impact factor: 2.447

6.  A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.

Authors:  Jing Liu; Changqie Pan; Lihong Guo; Mengwan Wu; Jing Guo; Sheng Peng; Qianying Wu; Qiang Zuo
Journal:  J Hematol Oncol       Date:  2016-08-31       Impact factor: 17.388

7.  Increased MACC1 levels in tissues and blood identify colon adenoma patients at high risk.

Authors:  Hassan Ashktorab; Pia Hermann; Mehdi Nouraie; Babak Shokrani; Edward Lee; Tahmineh Haidary; Hassan Brim; Ulrike Stein
Journal:  J Transl Med       Date:  2016-07-20       Impact factor: 5.531

8.  Combination of Endothelial-Monocyte-Activating Polypeptide-II with Temozolomide Suppress Malignant Biological Behaviors of Human Glioblastoma Stem Cells via miR-590-3p/MACC1 Inhibiting PI3K/AKT/mTOR Signal Pathway.

Authors:  Wei Zhou; Libo Liu; Yixue Xue; Jian Zheng; Xiaobai Liu; Jun Ma; Zhen Li; Yunhui Liu
Journal:  Front Mol Neurosci       Date:  2017-03-13       Impact factor: 5.639

Review 9.  The potential therapeutic applications and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) in cancers.

Authors:  Ewa Katarzyna Kopczyńska
Journal:  Contemp Oncol (Pozn)       Date:  2016-09-05

10.  Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.

Authors:  Manisha Juneja; Dennis Kobelt; Wolfgang Walther; Cynthia Voss; Janice Smith; Edgar Specker; Martin Neuenschwander; Björn-Oliver Gohlke; Mathias Dahlmann; Silke Radetzki; Robert Preissner; Jens Peter von Kries; Peter Michael Schlag; Ulrike Stein
Journal:  PLoS Biol       Date:  2017-06-01       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.